Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/27/2003US20030220319 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders
11/27/2003US20030220318 New phenylalanine derivatives
11/27/2003US20030220317 Trypsin-like serine protease inhibitors; anticoagulants; side effect reduction
11/27/2003US20030220316 Such as N-(1-(1-methylethyl)piperidin-4-yl)-N-((4-methyl phenyl)methyl)-4-methoxyphenylacetamide for stimulation of serotonin receptors
11/27/2003US20030220315 Such as 3',3"-dibromo-4',4"-dimethoxy-5',5"-bis-(methoxycarbonyl)-1,1 -diphenylethene; for treating viral diseases/retroviruses
11/27/2003US20030220314 Dehydro-estriol (8-DHE3) and dehydro-pregnanetriol (7-DHPT), and methods of their synthesis
11/27/2003US20030220312 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
11/27/2003US20030220309 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors
11/27/2003US20030220308 Comprises lumisterol and tachysterol, for topical administration
11/27/2003US20030220307 Remedial agent for osteoporosis
11/27/2003US20030220304 Hydroxyphenstatin and the prodrugs thereof
11/27/2003US20030220303 GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD
11/27/2003US20030220302 Combination of flunixin or the meglumine salt with a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol
11/27/2003US20030220301 Metformin salts of lipophilic acids
11/27/2003US20030220300 Serve as a ligand for peroxisome proliferator-activated receptor gamma; e.g., ciglitazone, pioglitazone, troglitazone, darglitazone, englitazone, and 5-(5-nitro-2-phenylsulfanyl-benzylidene)-2-thioxo-thiazolidin-4-one.
11/27/2003US20030220299 Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
11/27/2003US20030220295 Epothilone derivatives
11/27/2003US20030220294 Cyclodextrin compositions and methods of treating viral infections
11/27/2003US20030220293 Having high dissolution profile and in vivo enhanced bioavailability
11/27/2003US20030220292 Treatment of erectile dysfunction
11/27/2003US20030220291 Compounds for the treatment of psychiatric or substance abuse disorders
11/27/2003US20030220290 E.g., beta-L-2'-deoxyadenosine
11/27/2003US20030220288 Nor-1 and nur77 nuclear receptors as targets for anti-leukemia therapy
11/27/2003US20030220285 Expression vectors for stimulating an immune response and methods of using the same
11/27/2003US20030220281 To inhibit the activity of elastase or cathepsin G, thereby inhibiting ectopic implantation of endometrial fragments.
11/27/2003US20030220280 Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration
11/27/2003US20030220279 Decreasing cell proliferation by decreasing levels of PP5
11/27/2003US20030220277 Methylation of plasmid vectors
11/27/2003US20030220272 Erythromycin type macrolide with a fused oxazolone ring
11/27/2003US20030220271 Motilide compounds
11/27/2003US20030220267 Especially HIV-1 protease inhibitors; peptides containing one or more B-OH groups
11/27/2003US20030220266 Administering an inhibitor of cyclooxygenase-1 and/or an EP2 and/or EP4 receptor antagonist to treat cervical cancer
11/27/2003US20030220245 Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds
11/27/2003US20030220241 Method of treating cancer
11/27/2003US20030220237 Pharmaceutical composition
11/27/2003US20030220235 Muteins of the CGRP 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers
11/27/2003US20030220232 Peptide with the sequence Gln-Tyr-Asn-Ala-Asp and derivatives differing from the original sequence by the addition, substitution, inversion, insertin, deletion or modification of one or more amino acids; sodium ion channel binder
11/27/2003US20030220230 Enhancement of iron chelation therapy
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030220226 Compounds and compositions for delivering active agents
11/27/2003US20030220225 Composition and method for reducing the risk or progression of cardiovascular, glaucoma and tardive dyskinesia diseases
11/27/2003US20030219898 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
11/27/2003US20030219893 Compositions and methods for the treatment of hepatitis C virus infection
11/27/2003US20030219887 Crystals of glucokinase and methods of growing them
11/27/2003US20030219847 Alpha-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase
11/27/2003US20030219837 Integrin ligand
11/27/2003US20030219789 36P6D5: secreted tumor antigen
11/27/2003US20030219785 Using conjugated ligand to specifically identify x-ray induced RNA sequences/genes; gene therapy; antitumor/antiproliferative agents; radiotherapy
11/27/2003US20030219727 Prodrugs of phosphonate nucleotide analogues
11/27/2003US20030219718 Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
11/27/2003US20030219501 Comprising ellagitannin and glycine; useful in relieving gastric hyperacidity or gastroesophageal reflux disorder
11/27/2003US20030219500 Drink for athletes; creatine plays a pivotal role in the regulation and homeostasis of skeletal muscle energy metabolism
11/27/2003US20030219499 Therapy of estrogen-associated disorders
11/27/2003US20030219495 To prevent or reverse hypotension, unstable angina, myocardial infarction or shock caused by the concomitant ingestion of a phosphodiesterase inhibitor such as sildenafil citrate and a NO-donor such as L-arginine or an organic nitrate
11/27/2003US20030219494 Compositions and methods of using them
11/27/2003US20030219490 Nanoparticulate megestrol formulations
11/27/2003US20030219489 Solid pharmaceutical dispersions with enhanced bioavailability
11/27/2003US20030219488 Sustained-release formulation of a cyclooxygenase-2 inhibitor
11/27/2003US20030219485 A core containing a mixture of glipizide, a hydrophilic polymer and other excipients, a semipermeable wall surrounding the core(impermeable to content of core permeable to fluids) and a release passageways through the wall
11/27/2003US20030219484 A dosage form containing at least one active ingredient, which comprises a core and a shell with one or more openings, and readily soluble in gastrointestinal fluid, surrounding the core
11/27/2003US20030219483 Osmotic device containing venlafaxine and an anti-psychotic agent
11/27/2003US20030219482 Multiparticulate compositions for once-a-day administration
11/27/2003US20030219481 A controlled release dosage form for oral administration containing aglipizide or salt, a controlled release matrix cotaining gelling agent, an ionizable gel strength enhcancer and an inert diluent
11/27/2003US20030219478 The filling of a pullulan based capsule including an aldehyde group in the molecule, or a precursor
11/27/2003US20030219477 Soft shell gelatin capsules containing non-steroidal anti-inflammatories
11/27/2003US20030219476 Administering to a mammal a pharmaceutical formulation containing mitoxantrone in a cardiolipin (a liposome), and a excipient to treat cancer and multiple sclerosis
11/27/2003US20030219474 A polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide and a lipid associated with such polynuclotide
11/27/2003US20030219473 A lipid based cochelate formed of a purified soy- based phospholipid such as soy phosphatidylserine, and a multivalent cation selected from calcium, magnesium and zinc
11/27/2003US20030219472 Compositions and method for transmucosal drug delivery and cryoprotection
11/27/2003US20030219471 Administering to a menstruating female a cycle of contraceptive therapy, including, for at least 42 successive days, the administration of a combination of an estrogen and a progestogen as contraceptive daily dosage
11/27/2003US20030219470 Electrical apparatus for heating to a desired temperature for improved administration of pharmaceutically active compounds
11/27/2003US20030219467 For increasing ruminant feed efficiency
11/27/2003US20030219465 Composition for delivery of dithranol
11/27/2003US20030219461 Treating inflammation by administering antibiotics (penicillin) and cyclooxygenase-2 inhibitor (celecoxib)
11/27/2003US20030219454 Isolated from Haemophilus paragallinarum; for vaccinating chickens against infectious coryza
11/27/2003US20030219453 Vaccines
11/27/2003US20030219440 Administering enzyme inhibitors as antagonists to biosynthesis of 4,5,6-trihydroxy-2-oxohexanal; wrinkling and aging resistance
11/27/2003US20030219438 Human antibodies that bind human TNFalpha
11/27/2003US20030219432 Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
11/27/2003US20030219431 Treatment of neuronal and neurological damage associated with spinal cord injury
11/27/2003US20030219428 Deoxyribonuclease formed by genetic engineering, used for prophylaxis respiratory system disorders, lupus erythematosus and/or genetic disorders
11/27/2003US20030219427 Modulation of nuclear factor kappa beta activity using tumor progression locus (TPL-2) molecules; phosphorylation of proteins; controlling immune and inflammatory responses
11/27/2003US20030219413 Method for overexpression of zwitterionic polysaccharides
11/27/2003US20030219401 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
11/27/2003US20030219400 Methods for treating or inhibiting neurotoxin-mediated syndromes
11/27/2003US20030219393 Inhibitors of melanocyte tyrosinase as topical skin lighteners
11/27/2003US20030219392 Composition to enhance permeation of topical skin agents
11/27/2003US20030219389 Tooth whitening products
11/27/2003US20030219380 Indolinone drug; controlling cell differentiation, cell proliferation
11/27/2003US20030219379 Antiproliferative agent
11/27/2003US20030219377 Brain disorders; Alzheimer's disease
11/27/2003US20030219354 Deactivation pathogens; using riboflavin sensitizers; exposure to light source
11/27/2003US20030217908 Method and apparatus for transferring substrates
11/27/2003CA2855359A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2855306A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2830619A1 Glucan-based vaccines
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752143A1 Delivery of nucleic acid-like compounds
1 ... 5262 5263 5264 5265 5266 5267 5268 5269 5270 5271 5272 5273 5274 5275 5276 5277 5278 5279 5280 5281 5282 ... 7860